Related Experiment Videos
Temporary disappearance ("eclipse") of LPC-1 plasmacytoma M component synthesis following tumor cell transfer
Abstract:
The early phase of LPC-1 plasmacytoma development was studied by in vivo labeling with [6-14C]arginine using its M component (immunoglobulin G 2a,kappa) as marker. At a time when M component was not detected or faint by protein staining of electrophoretograms, significant labeling of M component was detectable by autoradiography. Labeling of the M component was fairly constant for the first 10 hr but was markedly decreased from Days 1 to 7. Nadir (0 to 3% of initial 30-min value) was observed on Day 3. Recovery of M component labeling to the 30-min level was complete by Day 13. This period of marked reduction or "eclipse" in newly synthesized M component was shortened by 2 days when mice were pretreated with pristane or cyclophosphamide prior to tumor cell transfer. The eclipse period was also 2 days shorter in athymic BALB/c-nu/nu mice than in normal BALB/c mice. The eclipse period corresponds to the classical "lag" following tumor cell transfer before tumor growth can be detected by conventional methods. The sensitivity of the [6-14C]arginine pulse permits the in vivo detection of small numbers of tumor cells (as few as 10(6) cells) over the early time periods after cell transfer. Modification of eclipse by manipulating host and/or tumor cells may elucidate the accompanying cellular and biochemical events.
Insights
Researchers used [6-14C]arginine to track LPC-1 plasmacytoma development. Early tumor cell growth, undetectable by standard methods, was revealed by M component labeling, offering insights into tumor progression.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- LPC-1 plasmacytoma is a model for studying early tumor development.
- The M component (immunoglobulin G 2a,kappa) serves as a specific tumor marker.
- Conventional methods often fail to detect minimal tumor burden in early stages.
Purpose of the Study:
- To investigate the early phase of LPC-1 plasmacytoma development in vivo.
- To utilize [6-14C]arginine labeling to detect nascent tumor cell activity.
- To characterize the 'eclipse' period following tumor cell transfer.
Main Methods:
- In vivo labeling of LPC-1 plasmacytoma cells with [6-14C]arginine.
- Quantification of M component labeling by autoradiography.
- Comparison of labeling patterns in normal and manipulated host environments (e.g., pristane, cyclophosphamide, athymic mice).
Main Results:
- Significant M component labeling was detected by autoradiography even when protein staining showed no or faint M component.
- A marked reduction ('eclipse') in newly synthesized M component labeling occurred between Days 1 and 7 post-transfer, with a nadir on Day 3.
- This 'eclipse' period was shortened by interventions like pristane, cyclophosphamide, or using athymic mice.
- The [6-14C]arginine pulse method detected as few as 10(6) tumor cells.
Conclusions:
- The [6-14C]arginine pulse labeling technique is highly sensitive for detecting early tumor cell proliferation.
- The 'eclipse' period represents a lag phase in tumor growth, detectable via sensitive molecular markers.
- Modulating host or tumor cell factors can alter this early tumor development phase, offering avenues for further research.